Franco Aversa | Researchain

Archive Network Publication Hotspot Collaboration

Hotspot

Bubble
[Coming Soon]

Cloud

Mosaic
[Coming Soon]

European Journal of Cancer | 1996

58 O - Successful engraftment of t-cell-depleted HLA-incompatible transplants

Franco Aversa; A. Terenzi; A. Tabilio; Andrea Velardi; F. Falzetti; L. Ruggeri; Sodani; P.T. Zei; C. Giannone; R. Jacucci; Yair Reisner; M. F. Martelli

Since March 1993, 48 patients (mean age 22 years, range 2–51) with high-risk or advanced stage leukemia (14 AML, 31 ALL, 3 CML) have been transplanted. 26 were in hematological remission (5 CR I, 20 CRxa0≥xa0II. 2nd CP of CML) and 22 (11 AML, 9 ALL. 2 BT) in chento-resistant relapse at the time of transplant. All donors were HLA-haploidentical “three loci” incompatible family members. The first 36 patients received a conditioning regimen that included single TBI (8xa0Gy), 25xa0mg/kg rabbit ATG. 10xa0mg/kg thiotepa and 100xa0mg/kg cyclophosphamide (Cy). In the last 12 Cy was replaced by fludarabine (40xa0mg/m2/day for 6 days) and thiotepa increased to 13xa0mg/kg. T-cell-depletion of the bone marrow and the PBPCs by the soybean agglutinin and E-rosetting technique was the sole prophylaxis for GvffD in the first 36 patients, while a CD34-selection of E-rosetted PBPCs bas been used for the last 12 cases. 46 patients engrafted. GvHD occurred in 6; 9 re1apsed. 18 survive. 16 event-free at a median follow. Up of 12 months (range 1–33) The details of the clinical data will be presented.

Thomas’ Hematopoietic Cell Transplantation, Fifth Edition | 2009

Hematopoietic Cell Transplantation from Human Leukocyte Antigen Partially Matched Related Donors

Claudio Anasetti; Franco Aversa; Andrea Velardi

Archive | 2016

Running title: Tregs in haploidentical transplantation

Mauro Di Ianni; F Falzetti; Alessandra Carotti; Adelmo Terenzi; Flora Castellino; Elisabetta Bonifacio; Beatrice Del Papa; Tiziana Zei; Iacucci Ostini; Debora Cecchini; Teresa Aloisi; Katia Perruccio; Loredana Ruggeri; Chiara Balucani; Antonio Pierini; Aristei C; Brunangelo Falini; Yair Reisner; Andrea Velardi; Franco Aversa; Massimo F. Martelli

Archive | 2014

T-cell adoptive immunotherapy prevents acute leukemia relapse HLA-haploidentical transplantation with regulatory and conventional

Brunangelo Falini; Andrea Velardi; Tiziana Zei; Roberta Iacucci Ostini; Debora Cecchini; Rita Tognellini; Yair Reisner; Franco Aversa; Maria Speranza Massei; Lucia Amico; Elena Urbani; Massimo F. Martelli; Loredana Ruggeri; F Falzetti; Alessandra Carotti

Archive | 2013

transplanted patients in hematopoietic Aspergillus fumigatus T-cell responses to + restricted memory CD8 - TLR3 essentially promotes protective class I

Andrea Velardi; Franco Aversa; Luigina Romani Moretti; Katia Perruccio; Rossana G. Iannitti; Francesca Fallarino; Antonio Pierini; Agostinho Carvalho; Silvia Bozza; Cristina Cunha; Carmen D'Angelo

Archive | 2010

Deploying Natural Killer Cell Allotherapy in the Setting of HLA-Haplotype-Mismatched Hematopoietic Stem Cell Transplantation

Andrea Velardi; Loredana Ruggeri; Antonella Mancusi; Franco Aversa; Massimo F. Martelli

Blood | 2005

Hematopoietic Stem Cell Transplantation (HSCT) from Alternative Donors for Acute Leukemia at High-Risk of Relapse. The Haploidentical Option.

Franco Aversa; A. Tabilio; Adelmo Terenzi; Stelvio Ballanti; Alessandra Carotti; Franca Falzetti; Andrea Velardi; Teresa Aloisi; Leonardo Flenghi; Jean Pierre Saab; Yair Reisner; M. F. Martelli

Annual Meeting Faculty of Medical Sciences Lebanese University | 2001

Mismatched hematopoietic stem cell transplantation in acute leukemia achievements to date and future prospects

Franco Aversa; Jean Pierre Saab; Massimo F. Martelli

Société Européenne d'Oncologie | 2000

High dose therapy in chronic myeloid leukemia

Franco Aversa; Jean Pierre Saab

Revue médicale libanaise | 2000

High dose therapy in acute leukemia

Franco Aversa; Jean Pierre Saab

Explore More